Orion Biotech Opportunities Corp. Warrant
ORIAW
ORIAW was delisted on the 28th of April, 2023.
19 hedge funds and large institutions have $2.95M invested in Orion Biotech Opportunities Corp. Warrant in 2021 Q3 according to their latest regulatory filings, with 19 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$312K |
| 2 |
FTCM
Fir Tree Capital Management
New York
|
+$260K |
| 3 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
+$208K |
| 4 |
SCC
Spring Creek Capital
Wichita,
Kansas
|
+$208K |
| 5 |
ACA
Arena Capital Advisors
Los Angeles,
California
|
+$156K |
Top Sellers
ORIAW Hedge Fund Activity: Q3 2021 in Review
19 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Orion Biotech Opportunities Corp. Warrant (ORIAW) for Q3 2021, worth a combined $2.95M.
Buyers outnumbered sellers: 19 funds opened new ORIAW positions and 0 closed out — a net gain of 19 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was 683 Capital Management, opening a new position worth an estimated $312K.
- 19 institutional investors held Orion Biotech Opportunities Corp. Warrant (ORIAW) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $2.95M of Orion Biotech Opportunities Corp. Warrant stock for Q3 2021.
- 19 funds opened new Orion Biotech Opportunities Corp. Warrant positions in Q3 2021 and 0 closed out, a net change of +19 holders.
- The largest Orion Biotech Opportunities Corp. Warrant buyer in Q3 2021 was 683 Capital Management, an estimated $312K added.
Based on aggregated 13F filings for Q3 2021.